Literature DB >> 11027803

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.

M J McCluskie1, H L Davis.   

Abstract

We have previously demonstrated that synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs (CpG ODN) are potent adjuvants in mice when delivered by intramuscular, intranasal and subcutaneous routes. Herein, using tetanus toxoid (TT) as a model antigen in BALB/c mice, we compared the ability of CpG ODN to induce mucosal and systemic humoral immune responses when antigen was delivered by three different routes: intrarectal, intranasal and oral. Results showed differences in immune responses with the three routes and also revealed that non-CpG "control" ODN had adjuvant effects when used at mucosal sites. This was unexpected since non-CpG ODN do not have such immunostimulatory effects in vitro or after parenteral immunization. These findings were further investigated after oral delivery of a killed influenza vaccine on its own as well as combined with TT and hepatitis B surface antigen. Our findings demonstrate that with mucosal delivery, there is a Th2 immunostimulatory effect associated with the phosphorothioate ODN backbone, and that the presence of CpG motifs shifts this towards a Th1 response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027803     DOI: 10.1016/s0264-410x(00)00208-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

2.  Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants.

Authors:  Rodolfo E Bégué; Alyson Moll
Journal:  Open Vaccine J       Date:  2009-01-01

3.  Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

Authors:  Sang-Moo Kang; Qizhi Yao; Lizheng Guo; Richard W Compans
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice.

Authors:  K Kitagaki; T R Businga; J N Kline
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 5.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

6.  Therapeutic implications of orally delivered immunomodulatory oligonucleotides.

Authors:  Dennis M Klinman
Journal:  Mol Ther       Date:  2015-02       Impact factor: 11.454

7.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.

Authors:  Hemanth Ramaprakash; Cory M Hogaboam
Journal:  Int Arch Allergy Immunol       Date:  2009-12-16       Impact factor: 2.749

9.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Authors:  Robert B Couch; Robert L Atmar; Thomas R Cate; John M Quarles; Wendy A Keitel; Nancy H Arden; Janet Wells; Diane Niño; Philip R Wyde
Journal:  Vaccine       Date:  2009-07-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.